Oncology & Cancer

New insights into how the drug pomalidomide fights cancer

Multiple myeloma is a cancer of the white blood cells, and patients diagnosed with this disease commonly die within five years. Clinicians often treat multiple myeloma with the drug thalidomide and structurally similar drugs ...

Oncology & Cancer

Treatment beneficial in smoldering multiple myeloma

(HealthDay)—For patients with smoldering multiple myeloma, treatment with lenalidomide plus dexamethasone correlates with delayed progression and improved survival, according to a study published in the Aug. 1 issue of ...

Oncology & Cancer

Lenalidomide may delay onset of myeloma-related bone, organ damage

The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Results of the study, which ...

Oncology & Cancer

New myeloma treatment options show promise

(HealthDay)—New multiple myeloma treatment options appear promising for patients aged 65 years and younger and for newly diagnosed patients who are ineligible for stem-cell transplantation, according to two studies published ...

Oncology & Cancer

New drug shows promise for myeloma patients

(HealthDay) -- Three new studies confirm that the drug lenalidomide can significantly lengthen the time that people with multiple myeloma experience no worsening of their disease, either after having a stem cell transplant ...

Medications

Daratumumab cuts risk for progression in multiple myeloma

(HealthDay)—For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published ...

page 2 from 4